Equities Analysts Set Expectations for Indaptus Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Indaptus Therapeutics in a note issued to investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07.

Indaptus Therapeutics Stock Down 4.7 %

Shares of NASDAQ:INDP opened at $2.66 on Tuesday. Indaptus Therapeutics has a twelve month low of $1.56 and a twelve month high of $4.08. The stock has a market capitalization of $22.72 million, a PE ratio of -1.45 and a beta of 1.28. The firm’s 50 day moving average price is $2.13 and its 200-day moving average price is $2.10.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of INDP. Citadel Advisors LLC bought a new stake in shares of Indaptus Therapeutics in the fourth quarter valued at about $29,000. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the first quarter valued at approximately $41,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the 2nd quarter worth approximately $51,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $78,000. Finally, Vanguard Group Inc. boosted its position in Indaptus Therapeutics by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after purchasing an additional 5,517 shares in the last quarter. 7.06% of the stock is owned by hedge funds and other institutional investors.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.